Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates

Company Performance - Personalis reported a quarterly loss of $0.18 per share, better than the Zacks Consensus Estimate of a loss of $0.23, and an improvement from a loss of $0.26 per share a year ago, representing an earnings surprise of 21.74% [1] - The company posted revenues of $20.61 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 18.20%, compared to year-ago revenues of $19.53 million [2] - Over the last four quarters, Personalis has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Outlook - Personalis shares have declined approximately 26.3% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.24 on revenues of $17.49 million, and for the current fiscal year, it is -$0.94 on revenues of $83.99 million [7] Industry Context - The Medical - Generic Drugs industry, to which Personalis belongs, is currently ranked in the top 17% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the industry outlook can significantly impact stock performance [5][8]